ODTX Stock Forecast: Odyssey Therapeutics, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Odyssey Therapeutics, Inc. hold a median 12-month price target of $30 — +65.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ODTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Odyssey Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (46): Smaller than most of the companies we track.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Odyssey Therapeutics, Inc. — and when they’d sell — is the membership.
ODTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ODTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +65.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 June 2026 | Oppenheimer | Reiterates | Outperform | $40 |
| 2 June 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 2 June 2026 | JP Morgan | Initiates | Overweight | — |
| 2 June 2026 | Oppenheimer | Initiates | Outperform | — |
| 2 June 2026 | TD Cowen | Initiates | Buy | — |
| 2 June 2026 | Wedbush | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ODTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Odyssey Therapeutics, Inc. (ODTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.5×
- Price / sales
- 859.4×
- Price / book
- −1.7×
- EV / EBITDA
- −10.0×
Cheaper than 88% of US stocks
Cheaper than 1% of US stocks
Cheaper than 95% of US stocks
Cheaper than 84% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −14232.4%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
- Return on equity
- 30.4%
- Return on assets
- −55.1%
- Dividend yield
- —
Higher than 88% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ODTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ODTX appears on the weeks it earns a place.
Frequently asked questions about ODTX stock
What is the ODTX stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Odyssey Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $26 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ODTX stock a buy right now?
Of the 5 analysts covering Odyssey Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Odyssey Therapeutics, Inc. 0 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ODTX?
As at 1 Aug 2026, Odyssey Therapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (46 of 100).
Will ODTX stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +65.5% from the last close, and Ticker Nerd's factor model ranks Odyssey Therapeutics, Inc. 0 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ODTX stock forecast for 2030?
No analyst covering Odyssey Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ODTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $40 over the next 12 months.
What does Odyssey Therapeutics, Inc. do?
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune and inflammatory diseases.
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune and inflammatory diseases. The company advances a pipeline of small molecule and protein therapeutics that target upstream signaling nodes in the innate immune system to prevent pathological inflammation. Key programs include OD-001, an oral small molecule RIPK2 scaffolding inhibitor for ulcerative colitis and Crohn’s disease; OD-002, an SLC15A4 inhibitor for cutaneous lupus erythematosus, nephropathies, and B cell-mediated diseases; and OD-003, a TNFR2 agonist protein therapeutic for atopic dermatitis, systemic lupus erythematosus, and alopecia areata. Additional candidates address TSLP/IL-33 for asthma and COPD, IRAK4 scaffolding for atopic dermatitis and hidradenitis suppurativa, and IRF5 in collaboration with partners. Founded in 2021 and headquartered in the United States, Odyssey Therapeutics leverages expertise in immunology to create precise treatments that modulate inflammatory dysregulation, aiming to address significant unmet needs in immunology through selective targeting of disease-relevant pathways.
CEO Dr. Gary D. Glick Ph.D. · 100 employees · United States · https://odysseytx.com